Welcome to our dedicated page for BioMarin Pharmaceuticals news (Ticker: $BMRN), a resource for investors and traders seeking the latest updates and insights on BioMarin Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioMarin Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioMarin Pharmaceuticals's position in the market.
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that Alexander Hardy, President and CEO, will present at the 42nd Annual J.P. Morgan Conference on January 8, 2024. The presentation will be available via live audio webcast and archived on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced the appointment of three new independent directors, the establishment of a Strategic and Operating Review Committee, and cooperation and information sharing agreements with Elliott, to enhance corporate governance and long-term shareholder value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (BMRN) announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox), the first gene therapy for hemophilia to receive an approved federal price in Germany. The gross price of €28,933.53 per vial equates to approximately $900,000 per patient in net revenue to BioMarin, facilitating access to ROCTAVIAN for eligible individuals among the roughly 2,000 adults with severe hemophilia A in Germany. The agreement includes an outcome-based prospective cohort model for future reimbursement and ensures supply and reimbursement for eligible patients in Germany for a minimum term of 3 years. Final price negotiations with the Italian Medicines Agency are underway, and significant progress has been made with U.S. payers to increase access to treatment for approximately 2,500 eligible adults living with severe hemophilia A in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
Rhea-AI Summary
BioMarin Pharmaceutical Inc. announces narrowed financial guidance for full-year 2023. VOXZOGO approved for children without age restrictions in the US and for children aged 4 months and older in Europe. ROCTAVIAN reimbursement network on-track for global patient access. Full-year 2024 revenue expected to approach $3 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. has announced that Alexander Hardy will be the new president and CEO, succeeding Jean-Jacques Bienaimé, who will retire as chairman and CEO. Hardy, currently the CEO of Genentech, brings over 30 years of experience in the healthcare and biotechnology industries. Richard A. Meier will become the chair of the board of directors. Under Bienaimé's leadership, BioMarin has grown significantly and is expected to reach annual revenues of well over $2 billion in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical Inc. has received FDA approval to expand the indication for VOXZOGO® (vosoritide) to include children of all ages with achondroplasia. Previously, the drug was only approved for children aged 5 and older. VOXZOGO is the only approved treatment for achondroplasia and has shown positive results in improving linear growth in pediatric patients. The company has also seen strong patient demand for the medicine worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
Rhea-AI Summary
BioMarin Pharmaceutical to host conference call and webcast to discuss third-quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical announces new data on VOXZOGO in children with achondroplasia at ESPE Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
-
Rhea-AI Summary
BioMarin Pharmaceutical expects approval for the expansion of VOXZOGO in Europe in Q4 2023 and a decision from the FDA in the US on Oct. 21, 2023. VOXZOGO is currently approved in Europe for children aged 2 and older and in the US for children aged 5 and older. The expansion of VOXZOGO to younger ages has the potential to increase growth and other long-term benefits. BioMarin has seen strong demand for VOXZOGO since its introduction in 2021 and is working to meet additional demand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
Rhea-AI Summary
BioMarin Pharmaceutical to update investor community on research and development portfolio, including early-stage product candidates and new indication opportunities. Pipeline programs to be presented include treatments for hyperoxaluria, Duchenne muscular dystrophy, hypertrophic cardiomyopathy, and more. Potential advancements in the pipeline could drive future growth for BioMarin Pharmaceutical. No specific financial or market impact mentioned in the PR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
BioMarin Pharmaceuticals Inc
Nasdaq:BMRN
BMRN Rankings
BMRN Stock Data
15.68B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NOVATO
About BMRN
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment